Prion-Like Seeding of Misfolded α-Synuclein in the Brains of Dementia with Lewy Body Patients in RT-QUIC
- 3.4k Downloads
The prion-like seeding of misfolded α-synuclein (αSyn) involved in the pathogenesis of Lewy body diseases (LBD) remains poorly understood at the molecular level. Using the real-time quaking-induced conversion (RT-QUIC) seeding assay, we investigated whether brain tissues from cases of dementia with Lewy bodies (DLB), which contain serine 129 (Ser129)-phosphorylated insoluble aggregates of αSyn, can convert Escherichia coli-derived recombinant αSyn (r-αSyn) to fibrils. Diffuse neocortical DLB yielded 50% seeding dose (SD50) values of 107~1010/g brain. Limbic DLB was estimated to have an SD50 value of ~105/g brain. Furthermore, RT-QUIC assay discriminated DLB from other neurological and neurodegenerative disorders. Unexpectedly, the prion-like seeding was reconstructed in reactions seeded with oligomer-like species, but not with insoluble aggregates of r-αSyn, regardless of Ser129 phosphorylation status. Our findings suggest that RT-QUIC using r-αSyn can be applied to detect seeding activity in LBD, and the culprit that causes prion-like seeding may be oligomeric forms of αSyn.
Keywordsα-synuclein Real-time quaking-induced conversion (RT-QUIC) Prion Dementia with Lewy bodies (DLB)
The accumulation of abundant misfolded proteins in the brain is a defining feature of most neurodegenerative disorders. Lewy body diseases (LBD), such as dementia with Lewy bodies (DLB) and Parkinson’s disease (PD), are characterized by the presence of Lewy bodies (LB), which are filamentous cytoplasmic inclusions composed mainly of aggregated α-synuclein (αSyn). Although the pathogenic mechanisms have not been fully elucidated, LBD is thought to occur through the accumulation of LB, i.e., aggregated αSyn, in neurons and neurites.
The bulk of αSyn aggregates within LB are phosphorylated at serine 129 (Ser129), while αSyn in the normal brain undergoes very little phosphorylation. Phosphorylation at Ser129 is the dominant pathological characteristic and may be crucial in LB formation and the pathogenesis of LBD. Ser129 phosphorylation accelerates polymerization of recombinant αSyn (r-αSyn) , and overexpression of wild-type (WT) r-αSyn, but not nonphosphorylatable mutant with substitution of alanine for Ser129 (S129A), induced significant accumulation of LB-like inclusions in cultured cells . Other groups demonstrated that Ser129 phosphorylation inhibits the fibrillation of r-αSyn , and mutation of S129A increases inclusion formation in a Drosophila model . The study using Drosophila also revealed that the number of inclusion bodies is inversely correlated with toxicity to dopaminergic neurons, indicating that inclusion bodies protect against neuronal toxicity . However, studies in rat models using recombinant adeno-associated virus (rAAV) to overexpress WT and mutant αSyn indicated that nonphosphorylated αSyn is associated with more severe toxicity toward dopaminergic neurons than the phosphorylated form [5, 6], and that there are no significant differences in neurotoxicity between both forms . Thus, the significance of Ser129 phosphorylation of αSyn in the pathogenesis of LBD remains poorly understood.
Postmortem studies by Braak and colleagues showed that LB pathologies initially arise in the medulla oblongata and the olfactory bulb and then extend to the midbrain and the limbic areas, with subsequent spread to the neocortical regions in PD . In addition, the pathological stage appears to be closely linked to progression of lesions and clinical manifestations . The spread of LB in the brain suggests that pathological αSyn retains the ability to propagate as prions. Transplant studies provided evidence that LB are present in normal fetal mesencephalic neurons grafted into the striatum of patients with PD, indicating that the pathology could be transmitted from the host brain to grafted healthy neurons [10, 11]. Moreover, inoculation of pathological brain homogenates from A53T mutant human αSyn transgenic (Tg) mice showing motor clinical abnormalities into A53T Tg mice [12, 13, 14] resulted in LB-like aggregations derived from endogenous αSyn and cell-to-cell spread, and the A53T Tg mice showed reduced survival period . A similar prion-like phenomenon was also induced in WT mice inoculated with brain extracts from DLB patients  and A53T Tg mice inoculated with brain homogenates from multiple system atrophy (MSA) patients . Furthermore, introduction of synthetic fibrils formed from r-αSyn elicited intercellular transmission of pathological αSyn in primary neurons  and WT mice , which developed dopamine neuron loss that resulted in motor deficits. These reports suggested that αSyn behaves like a prion.
Previously, we developed an in vitro amplification technique, designated “real-time quaking-induced conversion (RT-QUIC),” for detection of prions in tissue and body fluids . This assay is based on the propensity of prions to act as seeds and replicate in an autocatalytic process that converts recombinant prion protein as a substrate into amyloid fibrils, which retain the prion infectivity and strain properties of the original prion . The present study was performed to investigate whether prion-like conformational conversion of r-αSyn is induced by brain tissue from patients with DLB using the RT-QUIC assay. More recently, it has been shown that RT-QUIC using r-αSyn can detect abnormal αSyn in the brain and cerebrospinal fluid (CSF) from DLB and PD . The RT-QUIC assay of CSF from DLB and PD showed 92 and 95% sensitivity, respectively, with an overall specificity of 100%. The study provides no data regarding the seeding activity and the form of abnormal αSyn. Furthermore, we performed quantitative analysis of abnormal αSyn seeding activity and examined the relationship between prion-like behavior and Ser129 phosphorylation or multimeric status of αSyn.
DLB brain tissues were obtained at autopsy from seven patients with histopathological confirmation of the clinical diagnosis. Of these subjects, six were classified as having diffuse neocortical DLB type (DN-DLB), and the remaining one case was limbic DLB type (Li-DLB) according to Braak staging. Brain tissues of prion disease were obtained at autopsy from three patients with sporadic CJD (sCJD) and one patient with GSS associated with a Pro to Leu mutation at codon 102 of PRNP (P102L). sCJD subtypes were diagnosed according to the genotype at codon 129 of the PRNP gene and the physicochemical properties of abnormal prion protein (PrPSc). They included two cases of type 1, codon 129 MM (MM1), and one case of type 2, codon 129 MM (MM2). Brain tissues with AD were obtained at autopsy from two patients that had received a neuropathological diagnosis of the presence of neurofibrillary tangles and neuritic plaques. The brain specimens were pure forms of AD with little or no coexisting LBD. Brain tissues from schizophrenia and breast cancer patients without histopathological changes in the brain were used as non-degenerative cases. All samples were taken from the frontal cortex and stored at −80 °C.
Recombinant Human α-Synuclein Expression and Purification
We prepared reaction mixtures in 96-well, optical, black-bottomed plates with a non-treated surface (Cat. No. 265301; Nunc) in a final total volume of 100 μl. The surface material was polystyrene. To avoid contamination, we prepared all materials inside a biological safety cabinet and used aerosol-resistant tips. The final concentrations of reaction buffer components were 50 mM HEPES (pH 7.5) and 10 μM Thioflavin T (ThT). The concentration of r-αSyn was 100 – 150 μg/ml, and only freshly thawed r-αSyn was used. Brain tissues (frontal cortex region) were homogenized at 10% (w/v) in ice-cold PBS supplemented with a protease inhibitor mixture (Cat. No. 11836170001; Roche) using a multi-bead shocker. After centrifugation at 2000 × g for 2 min, supernatants were collected and frozen at −80 °C until use. Brain homogenate was diluted with PBS prior to the reactions. r-αSyn, suspended in 95 μl of reaction buffer, was loaded into each well of a 96-well plate and mixed with 5 μl of brain homogenate. The 96-well plate was covered with sealing tape (Cat. No. 236366; Nunc) and incubated at 40 °C in a plate reader (Infinite M200 fluorescence plate reader; TECAN) with intermittent shaking, consisting of 40 s of circular shaking at the highest speed (432 rpm), no shaking for 20 s, and then a 2-min pause to measure the fluorescence. The fluorescence intensity on the bottom of the plate was read every 10 min to monitor the kinetics of amyloid formation using monochromators with excitation and emission wavelengths of 440 and 485 nm, respectively. Six replicates of each diluted brain homogenate sample were measured for 96 h. Each diluted sample of insoluble aggregates and oligomers of r-αSyn was assayed in three to four and three to six replicates for 72 h, respectively. The maximal fluorescence intensity in reactions with 5 × 10−5 and 5 × 10−6 dilutions of non-DLB cases and without seed was 97.3 ± 6.7 (means ± standard deviation) arbitrary units in total 90 wells within 96 h. In addition, none of the reactions reached a fluorescence intensity > 120 arbitrary units. Therefore, we designated positive reactions as those with fluorescence intensity > 120 arbitrary units and calculated the seeding dose giving a positive reaction in 50% of replicate reactions (SD50) using the Spearman–Kärber method as described previously . We observed slight variations in the optimal r-αSyn concentration (100 – 150 μg/ml) between the lots of r-αSyn, but the final sensitivity for DN-DLB case #1, which was used as the standard for calculating sensitivity, was approximately the same (SD50 values of 107 – 108/g brain).
Preparation of Insoluble Aggregates and Oligomers of r-αSyn for RT-QUIC Analysis
Wild-type or S129A r-αSyn (400 μg/ml) was incubated at 37 °C without agitation in the presence or absence of 4 U/μl of casein kinase 2 (CK2, Cat. No; P6010L, New England Biolabs Inc) or 200 μM ATP (Cat. No. A2383-1G; Sigma-Aldrich) in reaction buffer (20 mM Tris-HCl, pH 7.5, 50 mM KCl and 10 mM MgCl2). To obtain insoluble aggregates and oligomers of r-αSyn, the reactions were stopped after 264 and 5 h of incubation, respectively. After 264-h incubation, the mixture of insoluble r-αSyn aggregates was diluted in 50 mM HEPES buffer (pH 7.5) to a final concentration of 125 μg/ml r-αSyn and stored at −80 °C until use. After 5-h incubation, the mixture of r-αSyn oligomers was diluted in 50 mM HEPES buffer (pH 7.5) containing 10 μM ThT to a final concentration of 125 μg/ml r-αSyn and immediately subjected to RT-QUIC. The RT-QUIC products were stored at −80 °C until use.
Brain tissue (frontal cortex region) was lysed with Triton-deoxycholate (DOC) lysis buffer (50 mM Tris-HCl, pH 7.5, containing 150 mM NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate, 2 mM EDTA, and protease inhibitors) for 30 min at 4 °C. After 2 min of centrifugation at 2000 × g, the supernatant was collected, and its total protein concentration was measured using a bicinchoninic acid (BCA) protein assay kit (Cat. No. 23227; Pierce). Samples were boiled for 5 min at 95 °C with sodium dodecyl sulfate (SDS) loading buffer (62.5 mM Tris-HCl, pH 6.8, containing 5% 2-mercaptoethanol, 2% SDS, 5% sucrose, and 0.005% bromophenol blue) and subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were transferred onto an Immobilon-P membrane (Cat. No. IPVH304F0; Millipore) in transfer buffer containing 15% methanol at 300 mA for 2 h; the membrane was blocked with 5% nonfat dry milk in TBST (10 mM Tris-HCl, pH 7.8, 100 mM NaCl, 0.1% Tween 20) for 2 h at 4 °C and reacted with antibodies against αSyn (D119, Cat. No. BS3429; Bioworld Technology, Inc., RRID: AB_1662955, 1:2500), Ser129-phosphorylated αSyn (EP1536Y, Cat. No. ab51253; Abcam, RRID: AB_869973, 1:2500), Ser87-phosphorylated αSyn (Cat. No. sc-19893-R; Santa Cruz Biotechnology, RRID: AB_2192817, 1:500) or His-tag (Cat. No. 34670; Qiagen, RRID: AB_2571551, 1:1000). Immunoreactive bands were visualized by HRP-conjugated goat anti-rabbit IgG antibody (Cat. No. 111-035-003; Jackson ImmunoResearch Labs, RRID: AB_2313567) or goat anti-mouse IgG antibody (Cat. No. 115-035-003; Jackson ImmunoResearch Labs, RRID: AB_10015289), using an enhanced chemiluminescence system (GE Healthcare Life Sciences).
Transmission Electron Microscopy
Negative staining was performed on carbon supporting film grids, which were glow-discharged before staining. Aliquots of 5 μl of the samples were adsorbed onto the grids, and the residual solution was absorbed with filter paper. The grids were stained with 5 μl of freshly filtered stain (2% uranyl acetate). Once dry, the samples were viewed with a transmission electron microscope (JEM-1400PLUS; JEOL).
Circular dichroism (CD) spectra were measured with a JASCO J-820 spectropolarimeter (JASCO) using a quartz cell with a 1-mm path length. The CD spectrum was obtained by averaging four scans in the wavelength range of 195 – 250 nm. r-αSyn was dissolved in 20 mM sodium phosphate (pH 6.5) and 150 mM NaCl buffer. The concentration of r-αSyn was 300 μg/ml.
Fourier transform infrared spectroscopy (FTIR) spectra were measured with a Bruker Tensor 27 FTIR instrument (Bruker Optics) equipped with a mercuric cadmium telluride (MCT) detector cooled with liquid nitrogen. Aliquots of 20 μl of the sample were loaded into a BioATRcell II attenuated total reflectance-type reflectance unit. A total of 128 scans at 4-cm−1 resolution were collected for each sample under constant purging with nitrogen, corrected for water vapor, and the background spectra of the buffer were subtracted.
Histopathology and Immunohistochemical Staining
The brain tissues were fixed in 20% neutral buffered formalin, and 8-μm paraffin sections were prepared on glass slides with a microtome. After deparaffinization and rehydration, the tissue sections were subjected to staining with hematoxylin and eosin, and immunohistochemical staining using anti-Ser129-phosphorylated αSyn antibody (Cat. No. 015-25191; Wako, RRID: AB_2537218, 1:3000). To enhance the immunogenicity, the sections were prepared by heating for 40 min at 98 °C prior to incubation with primary antibody. Primary antibody binding was detected by the labeled streptavidin-biotin method (DAKO). Peroxidase-conjugated streptavidin was visualized with 3′3-diaminobenzidine (Cat. No. 7411-49-6; Wako) as the chromogen. Immunostained sections were lightly counterstained with Mayer’s hematoxylin.
The values of maximal fluorescence intensity and lag phase, the time required to reach a fluorescence intensity >120 arbitrary units, in reactions with brain homogenate within 96 h, or in reactions with oligomers of r-αSyn within 72 h on RT-QUIC were extracted, and then compared between dilutions including controls (reactions without seed or with mock sample) in each individual case or sample. In addition, the values in reactions with oligomers of r-αSyn were compared between samples at the same dilutions. Data for maximal fluorescence intensities were analyzed by one-way ANOVA, followed by the Tukey–Kramer test. The data for lag phase were subjected to log-rank and Tukey–Kramer tests. P < 0.05 or P < 0.01 was taken to indicate statistical significance.
Ser129-Phosphorylated α-Synuclein Is Abundant in the Brain from Dementia with Lewy Bodies
We next examined the biochemical properties of αSyn in brain homogenates (BH) from DLB patients by western blotting (Fig. 2b). Immunoblotting analysis of samples from all patients showed either a native αSyn band at 18 kDa, the dimeric form at 36 kDa, or both. The two cases of DN-DLB and one case of Li-DLB contained markedly bulky multimeric αSyn, which was in the mass range of > 250 kDa. The insoluble multimer was more abundant in DN-DLB than Li-DLB, indicating that αSyn multimer formation is critical to the disease progression. This band was not observed in non-DLB cases. All cases showed bands of various sizes in the mass range of around 50 – 250 kDa. These bands were probably due to the oligomeric and/or ubiquitinated αSyn, and did not differ significantly between cases. The antibody against pSer129-αSyn detected an apparent band at high molecular mass (> 250 kDa) in two cases of DN-DLB (Fig. 2c). A band of the same size was observed in one case of Li-DLB, but the intensity of immunoreactivity was much lower than in DN-DLB. In contrast, non-DLB cases showed no immunoreactivity to the antibody against pSer129-αSyn. These observations indicated the presence of an insoluble multimer of αSyn > 250 kDa in the DLB brain that was highly phosphorylated at Ser129. Furthermore, we estimated the levels of pSer129-αSyn in the brains of DLB cases by quantitative dot blot immunoassay following Phos-tag SDS-PAGE (Supplementary Fig. S1). The levels of pSer129-αSyn in DN-DLB cases #1 and #2 were 13.5 ± 0.4 and 3.7 ± 0.2 mg/g brain, respectively, and the level of Li-DLB was 0.06 ± 0.02 mg/g brain. The proportion of pSer129-αSyn to total αSyn in DN-DLB was higher than that in Li-DLB: DN-DLB case #1 (57.9% ± 1.5%), DN-DLB #2 (22.6% ± 1.2%), and Li-DLB (6.1% ± 1.7%). These results suggest that pSer129-αSyn is relevant to disease progression. A previous study indicated that the level of αSyn phosphorylated on Ser87 is also increased in the LBD brain . However, the antibody against Ser87-phosphorylated αSyn detected a dimeric band of 36 kDa, and there were no significant differences in levels of the Ser87-phosphorylated form between cases (Fig. 2d).
Conversion of the Soluble Form of Recombinant Human α-Synuclein into Amyloid Fibrils by RT-QUIC
Insoluble Aggregates of α-Synuclein Had Little or No Seeding Activity
Assignments and relative proportions of secondary conformations of WT or S129A r-αSyn incubated with CK2 and ATP for 0 (WT-0 h and S129A-0 h) or 264 h (WT-264 h and S129A-264 h). The secondary structure content was determined by curve-fitting analysis of amide I components
Oligomer-Like Forms of α-Synuclein Cause Prion-Like Propagation
The results of this study demonstrated that the formation of r-αSyn fibrils is induced by RT-QUIC using soluble r-αSyn only in the presence of BH from patients with DLB (Fig. 3a, b). The sodium dodecyl sulfate (SDS)-insoluble aggregates larger than 250 kDa detected only in DLB cases were specifically phosphorylated at Ser129 (Fig. 2c), and therefore we postulated that the insoluble aggregates of pSer129-αSyn confer prion-like seeding activity. Unexpectedly, however, the insoluble aggregates of r-αSyn with increased β-sheet structure had little seeding activity in both phosphorylated and nonphosphorylated states (Fig. 5e). Instead, the pre-fibrillar oligomers of r-αSyn exerted seeding activity both with and without phosphorylation (Fig. 6e, f). Our findings suggest that the soluble oligomeric, but not fully fibrillary, αSyn is a seeding species in vitro. Meanwhile, inoculation of fibrils generated from r-αSyn has been reported to induce prion-like spreading of pathological αSyn in WT mice . The synthetic fibrils were formed with agitation (1000 rpm at 37 °C), and sonicated briefly prior to inoculation into mice, whereas the insoluble aggregates of r-αSyn used in Fig. 5e were generated by incubation at 37 °C without agitation. The fibril samples obtained using agitation and sonication are likely to contain oligomeric forms of r-αSyn, because these procedures are known to cause fibril fragmentation, resulting in shorter fibrils [27, 28]. Moreover, the fibrils may undergo partial proteolytic degradation in vivo. Therefore, the prion-like properties of synthetic r-αSyn fibrils reported in previous in vivo studies may be causally related to r-αSyn oligomers present in the fibril preparation and/or produced by degradation in vivo. Previous studies have shown that oligomeric species of r-αSyn are internalized by primary neurons and neuronal cell lines and induce endogenous αSyn aggregation [29, 30]. Furthermore, there is substantial evidence suggesting that oligomeric forms of αSyn are responsible for neuronal cell death and neurodegeneration [31, 32]. In a postmortem study, levels of soluble αSyn oligomers were significantly higher in the brains of patients with DLB than AD and controls, while there were no significant differences in levels of total αSyn between the three groups . These reports support the suggestion that pre-fibrillar αSyn oligomers represent the pathogenic species with prion-like behavior in LBD rather than mature fibrils or amorphous aggregates. A similar approach using monomeric amyloid-β (Aβ) indicated that the protein misfolding cyclic amplification (PMCA) assay could detect seeding activity associated with Aβ oligomers present in CSF from patients with AD . Brain tissue from DN-DLB had SD50 values of 103.4 and 103.1/μg total αSyn in cases #1 and #2, respectively, and 102.1/μg total αSyn in Li-DLB (Fig. 3a, b), while the values of WT r-αSyn oligomers generated by RT-QUIC were 104.4 – 104.9/μg r-αSyn (Fig. 6e, f). It is unclear whether all of the r-αSyn in RT-QUIC reactions is present in oligomeric forms, but if so 3.2 – 10% and 1.6 – 5.0% of total αSyn are estimated to be oligomers in the brains of DN-DLB cases #1 and #2, respectively, and 0.2 – 0.5% in that of Li-DLB. Although the precise role of the LB insoluble aggregates remains unclear, cyto- and neuroprotective roles have been reported in studies using cell lines  and Drosophila . The seeding activity of S129A oligomers was higher than that of WT oligomers regardless of phosphorylation state (Fig. 6f), and small amounts of the insoluble aggregates were detected in reactions containing WT oligomers but not S129A oligomers on western blotting analysis (Fig. 6b). These results suggest that the insoluble aggregates confer protection against prion-like propagation of αSyn.
Although there were no significant differences in seeding activity of r-αSyn oligomers between Ser129-phosphorylated and nonphosphorylated forms, we found that the phosphorylation of r-αSyn accelerates self-assembly (Fig. 5a and Fig. 6a) consistent with previous reports . Previous studies showed that an increase in pSer129-αSyn level precedes the appearance of LB in the brains of patients with LBD  and is induced by oxidative stress, mitochondrial dysfunction , and proteasomal inhibition  observed in the LBD pathology. Furthermore, pSer129-αSyn has been reported to have a protective effect against neuronal dysfunction [5, 39]. These results suggest that pSer129-αSyn results from the protective mechanism against neuronal dysfunction. The pSer129-αSyn would then promote initiation of self-assembly into pre-fibrillar oligomers and mature fibrils.
Consistent with the previous report , RT-QUIC allowed the differentiation of DLB from other degenerative disorders, such as AD and prion diseases, as well as from non-degenerative cases, suggesting that r-αSyn is largely unaffected by the ability of other misfolded proteins, i.e., amyloid-β, tau, and PrPSc, to induce heterologous cross-seeding. Although there have been reports of cross-seeding interaction between αSyn and other misfolded proteins in vitro and in vivo , the effect on RT-QUIC reaction appears to be negligible. The discrimination of DLB from other degenerative disorders raises the possibility of application of specific detection using RT-QUIC to differential diagnosis. The brains from patients with DN-DLB had an SD50 value of 107–10/g brain, and that with Li-DLB was estimated to have an SD50 value of approximately 105.1/g brain. Thus, it was suggested that RT-QUIC has a higher detection sensitivity for DLB compared with testing for pSer129-αSyn using western blotting or ELISA and provided more precise brain biopsy or autopsy diagnosis. Several studies using ELISA or bead-based flow cytometric assay investigated the levels of total αSyn in the CSF and blood of patients with DLB and other synucleinopathies, but the results have been inconclusive and contradictory . Meanwhile, it was shown that the levels of soluble αSyn oligomers in CSF and blood of DLB and PD are elevated compared with those of AD and controls in ELISA [42, 43]. These reports support the suggestion that oligomeric forms of αSyn are significant and promising targets for diagnosis of LBD and suggest the diagnostic potential of RT-QUIC through seeding of oligomers from CSF and blood of patients with LBD. Thus, the use of RT-QUIC along with the existing ELISA specific for αSyn oligomers is likely to be particularly advantageous in the differential diagnosis of LBD. The sample size was a relatively small for comparison between the different types of DLB because Li-DLB was examined in only one case in this study. Further replication studies with larger samples are warranted to determine whether RT-QUIC is valuable for discrimination between the different types of LBD, as well as whether this assay can be used with body fluids or other tissues.
In this study, we demonstrated the feasibility of using RT-QUIC for laboratory detection of potential seeding species of αSyn. Our data provide further support for the suggestion that the oligomeric forms of αSyn are the seeding species that cause prion-like propagation and play a significant role in the pathogenesis of LBD. We believe that this new method represents a robust tool for clinical diagnosis, screening for potential drugs, and advances our understanding of the role of αSyn as a prion-like protein in LBD.
We thank Dr. Tsuyoshi Mori and Dr. Takayuki Fuse for helpful discussions, and Atsuko Matsuo for technical assistance. This work was supported by a grant-in-aid for challenging exploratory research (grant no. 25640029) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
K. Sano., R.A., and K. Satoh. designed the entire project. K. Sano and R.A. wrote the manuscript. K. Sano., D.I., and T.N. performed the experiments and analyzed the data. K. Satoh., Y.I., M.Y., and S.M. contributed to the collection of human specimens and provided information about subjects. R.A., K.M., and N.N. supervised and discussed the data.
Compliance with Ethical Standards
The study protocol was approved by the Ethics Committee of Nagasaki University Hospital (ID: 10042823) and registered with the University Hospital Medical Information Network (ID: UMIN000003301). Written informed consent for inclusion in the study was given by the families of all patients.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 26.Vlad C, Lindner K, Karreman C et al (2011) Autoproteolytic fragments are intermediates in the oligomerization/aggregation of the Parkinson’s disease protein alpha-synuclein as revealed by ion mobility mass spectrometry. Chembiochem : a European journal of chemical biology 12:2740–2744CrossRefPubMedGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.